Extract
In 2006, Denninget al.[1] first proposed, in theEuropean Respiratory Journal, the term “severe asthma with fungal sensitisation (SAFS)” to describe a distinct phenotype of severe asthma characterised by an elevated IgE-mediated response towards fungal allergens. Since then, SAFS has been widely studied and is generally considered to sit within a spectrum of disease ranging from uncomplicated asthma to frank allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) [2, 3]. Fungal sensitisation, particularly towardsAspergillusspecies, has been highlighted as a potential “treatable trait” in airway disease, with anti-fungal therapy and inhaled/oral corticosteroids forming the basis of treatment [2, 4, 5].
Abstract
Sensitisation toAspergillusis associated with increased exacerbations in patients with COPDhttp://bit.ly/3i4LVD9
Footnotes
Conflict of interest: J.D. Chalmers reports grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis and Insmed; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer and Zambon; outside the submitted work. J.D. Chalmers is the chief editor of theEuropean Respiratory Journal. J. Pollock reports travel support from Asthma and Lung UK (ATS Abstract Scholarship) and the British Association for Lung Research (BALR); outside the submitted work.
Support statement: This work was supported by Asthma and Lung UK. Funding information for this article has been deposited with theCrossref Funder Registry.
- ReceivedOctober 22, 2022.
- AcceptedNovember 17, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contactpermissions{at}ersnet.org